Axsome Therapeutics
CompanyUnited States
Axsome Therapeutics develops one asset, approved (zoledronic acid in bone metastases). Mostly small molecule acting on apoptosis, lipid and ceramide metabolism and FDPS; based in the United States.
- Assets
- 1
- Furthest
- Approved
- Trials
- 6
- Signals
- 0
Pipeline
1Inhibits farnesyl pyrophosphate synthase, preventing protein prenylation and osteoclast-mediated bone resorption.
ApprovedSmall moleculeApoptosisLipid and ceramide metabolismbone metastasescancer
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials7
- Similar companies6
Updated 7 Oct 2026 · 68 sources